Allergan doesn’t intend to make a formal offer following a dip in its share prices
Its technology could cut the early stage drug discovery process by four years, says the company
Will also access Merck’s big-selling Neurobion and the Nasivin nasal decongestant range
Tavalisse and Crysvita are set to treat patients with chronic ITP and XLH, respectively
The deal will create a new, independent European generics company